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ABSTRACT
The alkylating agent platinum is first-line chemotherapy treatment for high-
grade serous carcinomas (HGSC) of tubal-ovarian origin. Platinum compounds cause 
DNA damage and induce apoptotic cell death in the bulk tumor population. However, 
subpopulations of tumor cells may exhibit diverging behaviors from the bulk tumor due to 
an alternate stress response that diverts tumor cells from apoptotic death. In this study, 
we identified a salvage survival pathway in which G2-arrested tumor cells bypassed 
apoptosis and progressed through aberrant mitotic events to then emerge as a distinct 
subpopulation of viable large hyperploid cells but with uncertain long-term propagation 
potential. Platinum-induced large hyperploid cells were flow sorted and showed rare 
regrowth capacity as compared to their more proficiently regenerating non-hyperploid 
counterparts. However, detailed time-lapse microscopy provided direct evidence that 
these hyperploid cells were mitotically active and could divide successfully to produce 
viable daughter cells. The hyperploid survival response was observed across different 
cell lines and utilization of this survival pathway was dependent on the strength of the 
G2-M checkpoint. Conceivably, this salvage survival strategy may contribute to increased 
genomic diversity of the regenerating tumor cell line through a coupled hyperploidization 
and de-polyploidization process that may be relevant for drug resistance.
INTRODUCTION
High grade serous carcinoma (HGSC) of tubal-
ovarian origin is an aggressive epithelial tumor with poor 
survival outcomes [1]. Platinum drugs are used as part 
of first-line therapy and exert genotoxic effects to tumor 
cells [2]. Major cellular responses to platinum treatment 
include initiation of the DNA damage response and the 
activation of the appropriate cell cycle checkpoint [3]. 
For tumor cells lacking a functional G1-S checkpoint 
such as in high grade serous carcinoma where the 
retinoblastoma (RB) and p53 pathways are perturbed, an 
arrest in cell cycle at the G2 phase is critical for DNA 
damage repair [4–6].
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The serine/threonine kinase CHEK1 (CHK1) is an 
important regulator of the G2-M checkpoint downstream 
of the ataxia telangiectasia and Rad3-related protein (ATR) 
kinase, activated by DNA damage from genotoxic agents 
or replicative stresses [7, 8]. ATR phosphorylates serine 
317 and 345 on CHK1, resulting in CHK1 conformational 
changes and enhanced kinase activity [9, 10]. Upon 
activation, CHK1 phosphorylates members of the CDC25 
family of phosphatases, leading to their inactivation and 
the subsequent maintenance of the mitotic cyclin complex 
(Cyclin B:CDC2) in its inactive state [11]. By stalling 
cells at the G2 phase, proper DNA damage repair can 
be performed to allow cell survival whereas irreparable 
double strand breaks would lead to apoptotic death [12].
While this well-established DNA damage response 
operates at a global level for the bulk tumor, there may 
be unique subpopulational behaviors that divert from 
this canonical stress response. An alternate pathway has 
been described wherein tumor cells may prematurely exit 
the G2-M checkpoint and progress through mitosis. The 
entry to mitosis with residual DNA damage often results 
in mitotic catastrophe-mediated cell death but occasional 
tumor cells may circumvent mitotic death by failure to 
complete telekinesis and revert back to a single cell state 
termed “mitotic slippage” [13]. Subsequent to slippage, 
the genome may undergo endo-reduplication to generate a 
subpopulation of viable polyploid cells [13, 14].
The mitotic progression and subsequent polyploidization 
process may explain the documented nuclear morphologic 
changes observed in patient tumors after neo-adjuvant 
chemotherapy treatment. While chemotherapy treatment 
induces apoptotic cell death in the tumor, there are additional 
morphologic changes within the treated tumor field that 
suggest alternate mode of cell death or occasional survival via 
non-canonical response to treatment. Several previous reports 
showed that residual tumor cells from post treatment resection 
specimens of high grade serous carcinomas developed nuclear 
enlargement and bizarre nuclear morphology [15–17]. We 
surmised these residual tumor cells bear the characteristics 
of hyperploidy. However, neither the DNA ploidy status of 
these tumor cells, nor the mechanism of their derivation and 
biological significance has been elucidated.
Part of the challenge with the evaluation and 
functional interrogation of these unusual hyperploid tumor 
cells originates from the difficulty to effectively follow 
the generation and the cell fate of this rare, dynamic 
subpopulation. We recently refined an image cytometry 
analytical approach that enables the rapid evaluation of 
the cell cycle and DNA ploidy state at the single cell level 
using the DNA-binding Hoechst-33342 dye (Yeung et 
al. manuscript in preparation). The cell cycle and DNA 
ploidy status are then additionally correlated with markers 
of key cellular programs such as the DNA damage 
response and G2-M cell cycle checkpoint pathway via 
immunofluorescence staining. As this approach analyzes 
all tumor cells within a population at the single cell level, 
distinct subpopulational responses to treatment within the 
bulk tumor cell line can be revealed.
Using this refined technical approach, here we 
demonstrate that platinum treatment induces nuclear 
enlargement in the surviving cell population of several HGSC 
cell line models, and this in-vitro observation resembles closely 
to the morphologic changes seen in-vivo in patient tumors 
after neoadjuvant chemotherapy treatment. We further show 
mechanistically that the nuclear enlargement phenomenon 
is a morphologic manifestation of the deregulation of the 
G2-M checkpoint, through which a subpopulation of tumor 
cell survivors transitioned to an intermediate hyperploid state. 
The significance of the hyperploid subpopulation is assessed 
by sorting and serial dilution plating experiments, which 
show rare colony outgrowths from a moderately enriched 
hyperploid fraction. More detailed time-lapse analysis 
illustrates the capacity for successful mitosis and cellular 
division by the hyperploid subpopulation, highlighting the 
possibility of progenies from this unique subpopulation 
to reside within the regenerating tumor. We propose the 
hyperploid pathway as a salvage survival strategy for the 
individual tumor cell otherwise facing apoptotic death, and 
potentially as a mechanism to maintain intra-tumoral diversity 
for the bulk tumor during chemotherapy treatment.
RESULTS
Platinum treatment resulted in apoptotic and 
necrotic cell death in the bulk tumor cell population
To evaluate the cytotoxicity effect of platinum 
treatment, cell survival was quantified by counts of 
propidium-iodide excluded nuclei. Adherent OVCAR3 
cells were treated with 10 µM to 160 µM carboplatin 
on day 0 for 24 hours, followed by removal of the drug. 
Surviving cells on day 1, 4, 7 or 11 were then processed for 
propidium-iodide and Hoechst 33342 staining for viability 
analysis. Figure 1A shows a time and concentration-
dependent cytotoxic effect of the carboplatin treatment, 
with half reduction of cell survival at 10 µM and complete 
elimination of the tumor cell population by the 160 µM 
treatment. Further time-lapse microscopy analysis of live 
Hoechst-stained OVCAR3 cells after similar carboplatin 
treatment revealed concentration-dependent increase in 
the rate of cell death (Figure 1B). Substantial level of cell 
death was already observed following the 80 µM to 160 
µM carboplatin treatment on day 1 whereas it was more 
gradual with the 10 µM to 40 µM treatment (Figure 1B).
To provide an overview of the major modes of 
cell death, the fraction of cells undergoing apoptotic or 
necrotic cell death was evaluated using a caspase 3/7 
activity indicator or the membrane impermeable dye 
propidium-iodide, respectively. Caspase 3/7 positive 
nuclei without propidium iodide indicate early apoptosis 
whereas caspase 3/7 and propidium iodide positive nuclei 
indicate late apoptosis. Propidium iodide staining alone 
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indicates necrosis. While there was a small baseline level 
of apoptotic and/or necrotic cell death in the control 
condition (Figure 1C, left panel), carboplatin treatment 
induced substantial increase in the fraction of cells 
undergoing apoptosis (early or late) or necrosis (Figure 
1C right panel), in a concentration and time-dependent 
manner (Figure 1D). Most of the platinum-mediated 
cell death was caspase 3/7 positive, suggesting the role 
of the apoptotic cell death program. However, up to half 
of the cell death at the late time point (day 11–12) was 
independent of apoptosis, suggesting the presence of other 
modes of cell death including necrosis (Figure 1D).
To further assess the role of apoptosis in mediating 
cell death by carboplatin, cells were treated with 
carboplatin and either vehicle or the pan-caspase inhibitor 
Emricasan (Figure 1E). The efficacy of Emricasan to 
inhibit apoptosis was observed in cells that exhibited less 
caspase 3/7 staining, and demonstrated a shift toward 
necrotic cell death (Supplementary Figure 1A). The IC50 
value for carboplatin cytotoxicity was 4.6 +/– 0.5 µM 
whereas the inhibition of apoptosis by Emricasan showed 
no statistically significant enhancement of the IC50 
value (7.0 +/– 0.8 µM; p = 0.4). The lack of enhanced 
survival with caspase inhibition suggests that the apoptotic 
pathway may not be the only dominant mode of cell death 
following platinum treatment at late time points.
Platinum-induced nuclear enlargement as a 
distinct cellular response among surviving tumor 
cells at intermediate to late time points
Apoptotic cell death is characterized by cell 
shrinkage, membrane blebbing, chromatin condensation, 
and nuclear fragmentation whereas necrosis is 
accompanied by organellar swelling and early disruption 
of membrane integrity. While the morphologic changes 
associated with apoptosis or necrosis reflected the bulk 
tumor cytotoxic response, we observed separate and 
distinct cellular response among the surviving tumor 
cells after platinum treatment. In contrast to dying 
cells, a portion of the surviving cells exhibited nuclear 
enlargement and bizarre nuclear shape changes. To 
systematically and quantitatively assess this nuclear 
response to platinum treatment, we applied a wide range 
of carboplatin concentrations to several representative 
ovarian cancer cell lines and monitored the change in 
nuclear area at different days after treatment. OVCAR3 
cells were treated with 0 µM to 160 µM carboplatin as 
described earlier and surviving cells on day 1 (Figure 2A), 
4 (Figure 2B), 7 (Figure 2C) or 11 (Figure 2D) were then 
fixed and processed for staining with the DNA-binding 
dye Hoechst 33342 to assess for changes in nuclear area. 
While carboplatin treatment did not cause significant 
nuclear area change after 24 hour, there was significant 
increase in nuclear area in the surviving cells starting 
from day 4 in a time and concentration-dependent manner 
(Figure 2E). The nuclear area, as determined only from 
the propidium-iodide excluded tumor cells, increased 1.6, 
2.3 and 3.0-fold at the IC50 (5 µM), IC80 (16 µM), and 
IC95 (62 µM) level, respectively (Figure 2F). Similar 
nuclear enlargement was also observed in the TOV3133G 
(Supplementary Figure 1B) and PEA1 (Supplementary 
Figure 1C) ovarian cancer cell lines, along with a SV40 
large T-antigen transformed lung epithelial cell line 
16HBE (Supplementary Figure 1D). In contrast, a non-
transformed fibroblast cell line HGF-1 did not show 
nuclear enlargement (Supplementary Figure 1E).
More importantly, these in-vitro derived large 
surviving tumor cells resembled closely those identified in 
a subset of patient tumors of high grade serous carcinoma 
(HGSC) after neo-adjuvant chemotherapy treatment 
(Figure 2G). From a cohort of ten resection specimens of 
HGSC obtained after chemotherapy treatment, five cases 
were found to exhibit these unusual nuclear morphologic 
changes (Supplementary Figure 2). While there was a 
baseline level of nuclear pleomorphism and nuclear area 
variation associated with high grade serous carcinoma, 
chemotherapy treatment induced substantial nuclear 
enlargement in a subpopulation of residual tumor cells 
beyond the usual variation. This was consistent with prior 
observations by McCluggage et al. where 9 of 9 matched 
HGSC showed increase in mean nuclear area of residual 
tumor cells in the post-treatment sample when compared 
to the pre-treatment sample (median increase = 1.3 fold; 
1.1–1.9 at the 25% or 75% percentile) [17]. Based on the 
similarity between the experimental in-vitro and the in-
vivo nuclear phenotype, we pursued further mechanistic 
analysis of these unusual large tumor cells induced by 
platinum treatment.
Nuclear area and DNA ploidy analysis revealed 
G2-arrest of tumor cells after platinum 
treatment followed by the de novo generation of 
a large hyperploid subpopulation
Surviving cells following platinum treatment were 
likely arrested at the G2 phase for DNA-damage repair 
and we hypothesized that the nuclear area change might 
be reflective of the change in cell cycle status. We recently 
developed a refined image cytometry analytical approach 
for cell cycle status assessment based on a previous 
report [18]. Using this approach (Yeung et al. manuscript 
in preparation), the DNA ploidy of OVCAR3 cells was 
identified based on total Hoechst DNA content as assessed 
from individual nuclei on confocal images detected 
using an automated nuclear segmentation algorithm. The 
baseline ploidy of the OVCAR3 cell line was reported 
to be in the sub- to near-triploid range [19]. Therefore, 
the triploid status (3N) would correspond to the cell 
cycle phase Go/G1, whereas the hexaploid status (6N) 
would correspond to the G2 phase. In addition to Hoechst 
staining, the use of EdU (5-ethynyl-2′-deoxyuridine) 
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Figure 1: Platinum treatment resulted in apoptotic and necrotic cell death in the bulk tumor cell population. Time course, 
dose response or live imaging experiment where adherent OVCAR3 cells maintained within 96-well plates were treated with carboplatin 
from 0 µM and up to 1000 µM for 24 hrs on day 0, followed by drug removal. For a typical time course experiment, a set of four similarly 
prepared 96-well plates were all treated on day 0 and then one plate within the set would be fixed on day 1, 4, 7 or 11. (A) Time course of 
cell survival showing propidium-iodide excluded, Hoechst-stained nuclei count at 1, 4, 7 or 11 days after carboplatin treatment with the 
indicated concentration. Data points were mean nuclei count per well indicating cell survival (normalized to control of day 1) +/– standard 
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pulse labeling enabled the identification of cells in the 
S-phase (Supplementary Figure 3). Gating to yield cells 
in the G1 (/Go), S and G2 phase of the cell cycle based 
on the Hoechst DNA ploidy and EdU incorporation level 
was then performed. Importantly, we further defined a 
threshold level to the right of the G2 gated region beyond 
which cells with supra G2 or hyperploid Hoechst DNA 
content (>6N) could be identified (Supplementary Figure 
3). The image cytometry analysis provides the nuclear 
area of individual tumor cells in conjunction with their 
associated DNA ploidy status, thereby establishing the 
relationship between nuclear area and DNA ploidy/cell 
cycle.
We applied this analytical method to assess changes 
in the cell cycle – DNA ploidy status of tumor cells after 
platinum treatment. We observed the accumulation of G2-
arrested OVCAR3 cells (6N) on day 4 after carboplatin 
treatment (Figure 3A), consistent with the known effect 
of this drug to induce G2 arrest [20]. Morphologically, 
the G2-arrested cells were moderately enlarged, with 
nuclear area 2 to 3-fold higher than cells in Go/G1 phase 
with 3N DNA content (Figure 3B). Interestingly, there 
was a hyperploid subpopulation with supra G2 Hoechst 
DNA content (>6N) that emerged on day 4 and its 
relative representation within the surviving population 
ranged from 15% to 40% on day 11 in a carboplatin 
concentration-dependent manner (Figure 3A). In addition, 
the hyperploid cells exhibited a 4-fold larger nuclear area 
when compared to cells with 3N DNA content (G1/Go) 
(Figure 3B). Therefore, we have identified the emergence 
of a subpopulation of large hyperploid tumor cells 
following carboplatin treatment.
To further assess the temporal relationship between 
the G2-arrested subpopulation and the hyperploid 
subpopulation, counting propidium-iodide-excluded, 
viable residual cells showed a biphasic kinetic pattern 
on the G2 subpopulation, with a maximum accumulation 
on day 4, followed by decline of this subpopulation 
(Figure 3C). This general trend was observed in all of 
the treatments except for the highest concentration of 
160 µM where the G2 subpopulation exhibited steady 
decline. Following and mirroring the decline of the 
G2 subpopulation, there was a rise in the hyperploid 
subpopulation (not only in relative ratios but also in 
absolute numbers), although its major rise was delayed to 
day 7 for most of the treatments (Figure 3D). Therefore, 
we have quantitatively determined that platinum 
treatment induced a subpopulation of large hyperploid 
cells de novo and that this subpopulation arose as the G2-
arrested subpopulation declined. This general pattern was 
modulated by treatment with the highest concentration 
of carboplatin (160 µM) in which both the G2 and the 
hyperploid subpopulation declined after treatment.
Dynamic changes in the G2 and hyperploid 
subpopulation due to deregulation of the G2-M 
checkpoint
We inferred from the initial rise and subsequent 
fall of the G2-arrested subpopulation that the G2-M 
checkpoint might be deregulated at the intermediate to 
late time point (Day 7–11) critical for the generation of 
the hyperploid subpopulation. To address this issue, we 
correlated the kinetics of the emergence of the supra G2 
subpopulation with the mitotic fraction and CHEK1 kinase 
(CHK1) activity to monitor a change in the status of the 
G2-M checkpoint.
The initial activation of the G2-M checkpoint 
after carboplatin treatment led to an accumulation of G2 
arrested cells most evident by day 4 and a concordant 
inhibition of mitosis in this early time period. As assessed 
by the mitotic marker phospho-Histone-H3, the mitotic 
rate of OVCAR3 cells was reduced after 24 hours of 
carboplatin treatment in a concentration-dependent manner 
deviations from 3 independent experiments. Nuclei analyzed ranged from 0 to about 20000 nuclei per well. **p < 0.01 and ****p < 0.0001 
using two-way ANOVA analysis with Bonferroni’s correction to demonstrate statistically significant differences between the 0 µM and the 
indicated carboplatin concentration. (B) Rate of cell death by time-lapse microscopy analysis from all causes after carboplatin treatment 
with the indicated concentration. Data points were mean percentage of cell death (based on the starting cell count) per hour +/– standard 
deviations from 3 independent experiments. Nuclei count ranged from 0 to 10000 nuclei per well. All death events ranged from 50 to 6000 
events per well over a 10 to 24 hour-interval. *p < 0.05, **p < 0.01, and ****p < 0.0001 using two-way ANOVA analysis with Bonferroni’s 
correction to demonstrate statistically significant differences between the 0 µM and the indicated carboplatin concentration. (C) Typical 
gating to quantify propidium-iodide positive and/or caspase indicator positive cells in the control (left; 6390 nuclei) or carboplatin treated 
condition (right; 4284 nuclei). Propidium-iodide and caspase indicator (CellEvent caspase 3/7 green indicator) positivity were defined on 
the plot of mean nuclear PI intensity vs. mean nuclear caspase indicator intensity to identify cells separated from the main viable cluster 
in the control sample. (D) Breakdown of percent viable, early apoptotic cell death (caspase-indicator positive), late apoptotic cell death 
(PI and caspase-indicator positive), or necrotic cell death (propidium-iodide positive) between day 1–2, 4–5, 8–9, 11–12. Data bars were 
mean percentage +/– standard deviations from 3 independent experiments. Nuclei analyzed ranged from 0 to 10000 nuclei per well. (E) 
Cell survival showing propidium-iodide excluded, Hoechst-stained nuclei count on day 11 after treatment with carboplatin on day 0 and 
either vehicle or the pan-caspase inhibitor Emricasan (2 µM or 5 µM). Emricasan was applied on day 0 or day 1 and then maintained and 
refreshed until the end of the experiment. Data points were mean nuclei count per well indicating cell survival (normalized to the 0 µM 
carboplatin condition) +/– standard deviations from 3 independent experiments. Nuclei analyzed ranged from 0 to about 17000 nuclei per 
well. The IC50 values from the two different conditions (4.6 +/– 0.5 µM vs. 7.0 +/– 0.8 µM) were not statistically significantly different 
(p = 0.4 using unpaired two-tailed t-test). 
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Figure 2: Platinum-induced nuclear enlargement as a distinct cellular response among surviving tumor cells at 
intermediate to late time points. Time course experiment where adherent OVCAR3 cells maintained within a set of four similarly 
prepared 96-well plates were all treated with 0 µM to 160 µM carboplatin for 24 hrs on day 0, followed by drug removal. One plate 
from the set of four was then fixed on day 1, 4, 7 or 11, respectively. (A–D) Hoechst 33342-stained nuclei, and where presented, the 
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and was further inhibited by day 4 (Figure 3E). The G2-
arrest and concomitant reduction of mitotic activity in 
carboplatin-treated cells may be attributed to the initiation 
of the DNA damage response by nuclear phospho-
H2A.X staining (Supplementary Figure 4A–4H) and the 
subsequent activation of the CHEK1 kinase as assessed by 
serine 345 phosphorylation (Supplementary Figure 4I–4P). 
These cellular responses exhibited up to 2.6-fold increase 
in nuclear pH2A.X staining (Supplementary Figure 4D) 
and 2-fold increase in CHK1 serine 345 phosphorylation 
in G2-arrested OVCAR3 on day 1 (Supplementary Figure 
4L). To further gauge the strength of the pCHK1 signal 
based on the amount of residual DNA damage burden, 
the pCHK1 response was normalized to the pH2A.X 
DNA damage response (Supplementary Figure 4Q–4U). 
The pCHK1/pH2A.X ratio also exhibited a biphasic 
kinetic pattern and its peak strongly correlated with the 
peak G2 arrest of carboplatin-treated cells on day 4 for 
all treatments except the highest concentration of 160 µM 
(Figure 3F). Therefore, the strength of CHK1 signaling 
from day 1 to day 4, and the accompanied G2-arrest and 
mitotic inhibition, all indicate a robust activation of the 
G2-M checkpoint.
To functionally demonstrate the role of CHK1 in 
maintaining G2-arrest, cells were treated with the CHK1 
kinase inhibitor AZD-7762 between day 1 and day 4 
after the initial carboplatin treatment. Figure 3G and 
Supplementary Figure 4V showed higher accumulation 
of hyperploid cells as early as on day 4 when checkpoint 
function was abolished, by percent representation or 
absolute count, respectively, indicating an earlier transition 
of G2-arrested cells to the hyperploid state.
Between day 4 and 7, the pCHK1/pH2A.X ratio 
declined substantially (Figure 3F). This change in 
pCHK1/pH2A.X ratio also corresponded to a fall in the 
G2 subpopulation (Figure 3C), followed by a new wave 
of mitotic activity as indicated by pHistone-H3 staining 
(Figure 3E). These results indicated an important 
reversal of the G2-M checkpoint status between the 
intermediate time point (day 4) and the later time points 
(day 7–11). Furthermore, the weakening of the G2-M 
checkpoint was tightly coupled to the rise of the supra 
G2 hyperploid subpopulation from day 7 to day 11, by 
absolute count (Figure 3D) or percent representation 
(Figure 3A).
For cells treated with the highest concentration of 
carboplatin (160 µM), the pCHK1/pH2A.X ratio exhibited 
a continuous declining pattern from the beginning, perhaps 
indicating an insufficiency of the pCHK1 response. This 
was also concordant with similar declining pattern of the 
respective G2 subpopulation as shown earlier (Figure 
3C). These results suggested that high concentration of 
carboplatin treatment might impede the initial establishment 
of the G2-M checkpoint or expedite its deactivation.
Time-lapse microscopy analysis revealed mitotic 
catastrophe as a cause of cell death and aberrant 
mitotic slippage events that may direct tumor 
cells toward a hyperploid state
The weakening of the G2-M checkpoint was tightly 
correlated with a new wave of mitotic activity and the 
rise of the hyperploid subpopulation, suggesting that 
checkpoint weakening could be coupled with mitotic 
progression and the emergence of hyperploidy. To 
ascertain whether there could be a mitotic outcome that 
may lead to a hyperploid state, we performed time-lapse 
recording of live Hoechst-stained OVCAR3 cells to 
follow the fate of mitotic events at various time points 
after carboplatin treatment. Time-lapse recordings 
showed a moderate level of mitotic activity for vehicle-
treated OVCAR3 cells on day 1, but the mitotic frequency 
subsequently subsided between day 4 and day 11 (Figure 
4A). More importantly, there was a significant carboplatin 
concentration-dependent reduction of mitotic activity 
between day 1 and day 4, followed by the emergence of 
a new wave of mitotic activity between day 8 and day 11 
(Figure 4A). The demonstration of a biphasic pattern of 
mitotic activity by time-lapse microscopy complemented 
our earlier results using the pHistone-H3 mitotic marker 
(Figure 3E).
Several major types of mitotic outcomes were 
observed in the time-lapse recordings and were classified 
by the following categories: successful division, mitotic 
catastrophe cell death, mitotic slippage, or mitotic events 
with unclear outcome (see below). Whereas most vehicle-
corresponding nuclear masks as identified by automated image analysis software for control vs. carboplatin treated cells on day 1 (A), day 
4 (B), day 7 (C) or day 11 (D). Scale bar = 20 µm. (E) Time course of median nuclear area for control vs. carboplatin treated cells. Data 
points were median nuclear area from each individual experiment and the connected line passed through the average of the three biological 
replicates. Median nuclear area assessed from well with at least 5 to about 20000 nuclei. **p < 0.01, ***p < 0.001 and ****p < 0.0001 using 
two-way ANOVA analysis with Bonferroni’s correction to demonstrate statistically significant differences between 0 µM and the indicated 
carboplatin concentration. (F) Carboplatin concentration-dependent effect on cell survival (blue curve) or median nuclear area (red curve) 
on day 11 is shown. Data points were mean nuclei count per well indicating cell survival (propidium-iodide excluded; normalized to 0 µM 
condition) or average of median nuclear area (normalized to 0 µM condition) +/– standard deviations from 3 independent experiments. 
Nuclei analyzed ranged from 1 to about 16000 nuclei per well. Median nuclear area assessed from well with at least 5 nuclei. *p < 0.05, **p 
< 0.01 and ****p < 0.0001 using two-way ANOVA analysis with Bonferroni’s correction to demonstrate statistically significant differences 
between 0 µM and the indicated carboplatin concentration. (G) Representative image of high grade serous carcinoma removed from the 
patient after neo-adjuvant chemotherapy treatment. Red arrowheads indicate several large tumor cells with marked nuclear enlargement due 
to the chemotherapy treatment whereas blue arrowheads indicate typical baseline morphology of HGSC tumor cells. Scale bar = 20 µm.
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Figure 3: Nuclear area and DNA ploidy analysis revealed the de novo generation of a subpopulation of large hyperploid 
tumor cells due to G2-M checkpoint deregulation. Time course or dose-response experiment where adherent OVCAR3 cells 
maintained within 96-well plates were treated with carboplatin from 0 µM and up to 1000 µM for 24 hrs on day 0, followed by removal 
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treated OVCAR3 cells on day 1 would undergo successful 
division leading to two daughter cells, most carboplatin-
treated tumor cells that progressed through mitosis died as 
a result of mitotic catastrophe (Figure 4B, 4D). However, 
there were temporal and carboplatin concentration-
dependent influences on the survival of these mitotically 
progressing tumor cells. Carboplatin treatment at 10 µM 
yielded a substantial percentage of cells that underwent 
successful mitosis (with a frequency of 25–30% on day 
8–11), whereas carboplatin concentrations of 20–40 µM 
were permissive for viability on day 1 but rendered most 
cells dead at later time points (day 8, 11) (Figure 4B). 
Moreover, carboplatin treatment resulted in an increased 
number of mitotic events with unclear outcomes, which 
included mostly protracted mitoses stalled at metaphase 
with no further progression within the recording period 
and a much smaller number of mitoses whose outcomes 
could not be resolved due to technical reasons (i.e. loss 
from the visual field). Overall, the contribution of mitotic 
catastrophe-mediated death to the total number of cell 
death events induced by carboplatin was found to be 
0.5%–6% (Figure 4C). However, the possibility should 
be considered that the mitotic death frequency could be 
somewhat underestimated due to technical reasons (i.e. 
recording frame rate, cell tracking difficulties). In any 
case, mitotic cell death was clearly detectable and might 
play a sizeable role in mediating the cytotoxic effects of 
platinum treatment.
In addition to cells that successfully completed 
mitosis or died by mitotic catastrophe, there was an 
alternate, non-lethal mitotic outcome through mitotic 
slippage events (Figure 4B). Mitotic slippage events 
were observed when cells initiated mitosis but 
prematurely exited this process by reverting back to 
the single-cell state, albeit with increased nuclear 
irregularities including extra lobation or multi-
nucleation (Figure 4E, orange arrow head) [21]. Time-
lapse recordings showed that higher concentration 
(40–80 µM) carboplatin treatments resulted in mitotic 
slippage events as early as day 1–2 whereas lower 
concentration treatments (10–20 µM) induced slippage 
events between day 8 and 12 (Figure 4B); however, 
technical factors associated with the time-lapse assay 
such as the recording frame rate (1 frame per 30 min) 
and method of cell tracking (visual/manual) could 
also potentially underestimate the mitotic slippage 
frequency. Based on the literature, it has been reported 
that a certain fraction of platinum induced damaged 
cells might undergo DNA endo-reduplication after 
mitotic slippage, resulting in hyperploid genome [13, 
14, 22]. Our kinetic analysis of carboplatin treated 
cells showed temporal overlap between the mitotic 
slippage events (Figure 4B) and the emergence of the 
hyperploid subpopulation (Figure 3D), supporting 
the notion that mitotic slippage could serve as a 
mechanism to generate hyperploidy in HGSC cells 
treated with platinum based drugs [13, 14, 22]. 
Therefore, the deregulation of the G2-M checkpoint 
and the subsequent mitotic slippage process might 
direct tumor cells toward a hyperploid state.
of the drug. For the time course experiment, one plate from a set of four was then fixed on day 1, 4, 7 or 11 for immunofluorescence 
or Hoechst staining. Only propidium-iodide excluded nuclei were used for quantification. (A) Time course of cell cycle phase/DNA 
ploidy distribution by total Hoechst DNA content. Data bars were the mean percentage of each subpopulation +/– standard deviations 
from 3 independent experiments. Nuclei analyzed ranged from 0 to about 20000 nuclei per well. (B) Median nuclear area of different 
subpopulations among the surviving cells on day 11 after carboplatin treatment. Data bars were the average of the median nuclear area 
of the indicated subpopulation (normalized to the Go/G1 of control) +/– standard deviations from 3 independent experiments. Median 
nuclear area assessed from well with at least 5 to about 20000 nuclei. Wells from the 160 µM carboplatin treatment were not included 
for analysis due to the very low number of surviving cells. **p < 0.01, ***p < 0.001 and ****p < 0.0001 using two-way ANOVA analysis 
with Bonferroni’s correction to demonstrate statistically significant differences between the G1/(Go) and the indicated subpopulation. 
(C–D) Time course showing nuclei count for the G2 subpopulation (C), or the hyperploid subpopulation with supra G2 DNA content (D) 
after carboplatin treatment with the indicated concentration. Data points were mean nuclei count per well (normalized to 0 µM of the G2 
(C) or hyperploid (D) subpopulation on day 1) +/– standard deviations from 3 independent experiments. Nuclei analyzed ranged from 
0 to about 20000 nuclei per well. *p < 0.05 and **p < 0.01 using two-way ANOVA analysis with Bonferroni’s correction to demonstrate 
statistically significant differences for the 10 µM treated condition between different day. (E) Time and concentration-dependent effect 
of carboplatin treatment on mitotic frequency as determined by percentage of nuclei positive for phospho-Histone-H3 staining. Positivity 
for pHistone-H3 staining was defined at the midpoint of the pH3 mean nuclear intensity histogram showing clear bimodal distribution. 
Data points were the mean percentage of pHistone-H3 positivity +/– standard deviations from 3 independent experiments. Percentage of 
pHistone-H3 positivity assessed from wells with at least 10 and up to about 20000 nuclei. *p < 0.05, **p < 0.01 and ****p < 0.0001 using 
two-way ANOVA analysis with Bonferroni’s correction to demonstrate statistically significant differences between the different treatment 
conditions. (F) Time course showing the ratio of the normalized pCHK1 response to the normalized DNA damage burden (CHK1 pS345 / 
H2A.X pS139) for the G2 subpopulation. The ratio was also normalized to the bulk control population of each day. Data points were mean 
values +/– standard deviations from 3 independent experiments. Nuclei analyzed ranged from 0 to about 20000 nuclei per well. Wells with 
fewer than 5 cells were not included for analysis. (G) Percentage of the hyperploid subpopulation on day 4 after initial treatment on day 0 
with carboplatin, followed by addition of vehicle or the CHK1 inhibitor AZD-7762 [200 nM] on day 1. Data points were mean percentage 
+/– standard deviations from 3 independent experiments. Nuclei analyzed ranged from 0 to about 24000 nuclei per well. *p < 0.05 and 
****p < 0.0001 using two-way ANOVA analysis with Bonferroni’s correction to demonstrate statistically significant differences between 
carboplatin treatment alone and the combination treatment.
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Figure 4: Time-lapse microscopy analysis revealed aberrant mitotic slippage events that may direct tumor cells toward 
a hyperploid state. Time-lapse microscopy experiment where OVCAR3 cells were treated with carboplatin (0 µM to 160 µM) on day 
0 and then live-imaged on day 1, 4, 8 or 11 at half-hour interval for 10 to 24 hrs. For (A–C), nuclei count ranged from 0 to 10000 nuclei 
per well. Time-lapse recordings from 6 to 8 imaged fields within a representative well were visually analyzed for each treatment condition, 
from which there were 0 (i.e. 160 µM on day 11–12) to about 1000 mitotic events per well over a 10 to 24 hour-interval (i.e. control on 
day 1–2). A. Time and concentration-dependent effect of carboplatin treatment on mitotic frequency as determined by visual analysis of 
time-lapse recording of cells for mitotic events. Data points were mean frequency (normalized to the 0 µM condition on day 1) +/– standard 
deviation from 3 independent experiments. *p < 0.05 and **p < 0.01 using two-way ANOVA analysis with Bonferroni’s correction to 
demonstrate statistically significant differences between 0 µM and the indicated carboplatin concentration or between the same treated 
concentration on different day. (B) Percentage breakdown of mitotic outcomes from visual analysis of time-lapse recordings of live mitotic 
events: successful mitotic division with the generation of two or more viable daughter cells = blue, mitotic catastrophe cell death = red, 
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Size-sorted hyperploid subpopulation showed 
differential regrowth potential compared to the 
non-hyperploid fraction
Carboplatin treatment resulted in the generation of a 
large hyperploid subpopulation (>6N) as well as cells that 
remained in the baseline non-hyperploid state (3N-6N). 
To assess whether the baseline non-hyperploid (3N-6N) 
and the large hyperploid subpopulation (>6N) possessed 
differential clonogenic potential, these two subpopulations 
were enriched by flow sorting and evaluated for 
proliferation. Control or 25 µM carboplatin-treated 
OVCAR3 cells on day 9 were flow sorted by size (forward 
scatter) and plated at varying density on the 96-well plate. 
The size-sorting for control OVCAR3 cells provided some 
enrichment of small-size cells (Supplementary Figure 
5A–5B and 5F) whereas size-sorting for carboplatin-
treated cells yielded distinct small vs. large subpopulations 
(Supplementary Figure 5C–5E and 5F). There was a good 
correspondence between cell size as indicated by forward 
scatter (small or high FSC) and the median nuclear area, 
suggesting that size sorting was able to enrich for the large 
abnormal cells for evaluation (Supplementary Figure 5G). 
Importantly, the small-size post-sorted carboplatin-treated 
subpopulation corresponded to cells with predominantly 
baseline non-hyperploid Hoechst DNA content (3N-6N) 
(Supplementary Figure 5H: mean of 86% of sorted cells) 
whereas the large-size sorting provided a mean of 3.7-
fold enrichment of the hyperploid subpopulation (>6N) 
(Supplementary Figure 5H: mean of 52% of sorted cells).
The growth within each well of the 96-well plate 
on day 30 (since the original treatment) was assessed 
by imaging of each well in its entirety after viable cells 
were processed for staining. The centroid location of each 
propidium-iodide excluded, Hoechst-stained viable cell 
within each well was plotted and shown in Figure 5A. 
The growth potential of small-size post-sorted control 
OVCAR3 cells was demonstrated at or beyond an initial 
plating density of 50 cells per well. Carboplatin treatment 
reduced the growth potential of the small-size post-
sorted subpopulation by about 5 to 10-fold (Figure 5A). 
For the large-size post-sorted subpopulation, there was 
more growth reduction, but not complete suppression as 
there was a rare area of growth in 1 of 8 wells plated at 
the 2000 cells per well density (Figure 5A). The growth 
potential of the large-size post-sorted carboplatin-treated 
subpopulation was estimated to be 1 in 20,000 cells, or 
about 40 to 80-fold less than the small-size post-sorted 
carboplatin-treated subpopulation. Results from three 
independent experiments were quantified in Figure 5B, 
where the growth within each well was assessed by 
percentage of surface area covered by the viable cell 
nuclei.
Because of the rarity of the growth events from the 
large-size post-sorted carboplatin-treated subpopulation, 
it was difficult to conclude whether these rare growth 
events were contributed by the hyperploid tumor cells or 
originated from the very small number of baseline non-
hyperploid tumor cells that could not be separated from 
the large hyperploid subpopulation. Also, the viability 
of the tumor cells might be affected by the mechanical 
manipulation involved during the flow sorting process, 
thereby reducing the growth potential of tumor cells. 
We further repeated the growth assay using hyperploid 
cells derived from carboplatin treatment at a lower 
concentration (12.5 µM) (Supplementary Figure 5I–5J) 
and observed more outgrowths (Figure 5C). Overall, 
the findings from the growth assay performed after 
flow sorting indicated that the baseline non-hyperploid 
(3N-6N) carboplatin-treated subpopulation might 
predominantly contribute to the regrowth of the tumor 
cell line. Nonetheless, the occasional outgrowths from 
the post-sorted hyperploid subpopulation (>6N) raised 
the possibility of contribution by this subpopulation. 
This notion prompted us to further evaluate the viability 
status and growth potential of this population using other 
complementary approaches.
Hyperploid tumor cells remained proliferative 
and retained capacity to generate viable 
daughter cells
To determine whether the reduced growth potential 
from the large-size post-sorted hyperploid subpopulation 
was due to reduced viability of the large hyperploid cells, 
we first assessed the viability status of the large hyperploid 
cells after carboplatin treatment. Adherent OVCAR3 
tumor cells within the 96-well plate on day 11 after 
carboplatin treatment were examined by antibody staining 
with an apoptotic marker, cleaved-PARP. The hyperploid 
mitotic slippage = green (defined as premature exit at metaphase-anaphase with no further progression to cytokinesis or re-unification of 
the daughter nuclei as one large irregularly lobated nucleus), unclear outcome = grey (which included mostly protracted mitoses stalled 
at metaphase or a smaller number of mitoses with ambiguous outcome due to technical issues from cells drifting out of focus/field or cell 
tracking). Data bars were mean percentage +/– standard deviations from 3 independent experiments. Conditions with fewer than 5 mitotic 
events were not shown for outcome analysis. (C) Contribution of mitotic catastrophe cell death to the overall cell death between day 1–2, 
4–5, 8–9, or 11–12. Data points were mean mitotic catastrophe death as a percentage of all death events +/– standard deviations from 3 
independent experiments. All death events ranged from 50 to 6000 events per well over a 10 to 24 hour-interval. (D) Images from time-lapse 
series of 10 µM carboplatin-treated cells undergoing mitotic catastrophe cell death on day 11 (arrowheads). Scale bar = 40 µm. (E) Images 
from time-lapse series of 10 µM carboplatin-treated cells going through mitotic slippage (orange arrowheads) or successful division (green 
arrowheads) on day 11. Scale bar = 40 µm. 
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Figure 5: Size-sorted hyperploid subpopulation (>6N) showed differential regrowth potential compared to the non-
hyperploid (3N-6N) fraction. Serial dilution growth assay where adherent OVCAR3 cells were treated with vehicle, 12.5 µM or 
25 µM carboplatin on day 0 for 24 hrs, followed by removal of the drug and further incubation of the cells until day 9. Cells were then 
detached, flow sorted by forward scatter (FSC) and propidium-iodide negativity into a small or large subpopulation, and then plated into a 
96-well plate at the indicated density for regrowth until final assessment by imaging on day 30. (A) The centroid location of each identified, 
propidium-iodide excluded, Hoechst stained cell within the wells of a 96-well plate was plotted on day 30, for the post-sorted control or 
post-sorted 25 µM carboplatin-treated subpopulation. (B) Final growth on day 30 as assessed by the total surface area of the well covered by 
tumor cell nuclei. The three groups were control (post-sorted FSC-small), or 25 µM carboplatin-treated (post-sorted FSC-small, post-sorted 
FSC-large). Data points were mean total covered surface area (normalized to the well with the largest growth) +/– standard deviations 
from 3 independent experiments. Nuclei analyzed ranged from 0 to about 27000 nuclei per well. (C) Final growth on day 30 from similar 
experiments as above where the three groups were control (post-sorted FSC-small), or 12.5 µM carboplatin-treated (post-sorted FSC-small, 
post-sorted FSC-large). Data points were mean total covered surface area (normalized to the well with the largest growth) +/– standard 
deviations from 3 sorting sessions. Nuclei analyzed ranged from 0 to about 67000 nuclei per well. *p < 0.05 and **p < 0.01, ***p < 0.001 and 
****p < 0.0001 using two-way ANOVA analysis with Bonferroni’s correction to demonstrate statistically significant differences between the 
indicated post-sorted subpopulation.
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cells were largely cleaved-PARP negative except for 
those derived from treatment with higher carboplatin 
concentration (80 µM) where cleaved-PARP positivity 
reached 50% (Figure 6A). To assess the proliferation 
status of the large hyperploid subpopulation, tumor cells 
were stained with an antibody to the proliferation marker 
Ki-67. The majority (80% to 90%) of the large hyperploid 
cells remained in the cell cycle whereas 20% to 50% of 
the baseline non-hyperploid subpopulation exited the cell 
cycle into quiescence (Figure 6B–6C).
As these results showed that the hyperploid tumor 
cells remained non-apoptotic and proliferative, we then 
assessed whether they may divide again to return to a 
non-hyperploid state by time-lapse microscopy. Live-cell 
recordings from OVCAR3 cells within the 96-well plate 
on day 11 after prior carboplatin treatment were analyzed. 
Importantly, there were large mono or bi-nucleated 
tumor cells with morphologic features characteristic of 
hyperploid cells that progressed through mitosis (Figure 
6D–6E). While these unusual mitotic events may primarily 
lead to mitotic catastrophe cell death or slippage events 
(Figure 6D; red, blue, orange arrowheads), we observed 
that a small number of these mitotic events from the 10 µM 
carboplatin treatment resulted in successful completion of 
division, producing viable daughter cells (Figure 6D–6E; 
green arrowheads). Additional analysis of the mitotic 
nuclei at this late time point confirmed that the mitotic 
nuclei were larger in size (Supplementary Figure 6A) 
and 40–45% of them had supra G2 hyperploid Hoechst 
DNA content (Figure 6F), indicating that these unusual 
mitoses originated from hyperploid cells. Therefore, the 
viability status and the frequent mitotic progression of 
the hyperploid cells illustrated the transient nature of the 
hyperploid state, and signified a predilection toward the 
return to a non-hyperploid state.
There appeared to be lower extent of residual DNA 
damage, as shown by pH2A.X staining, associated with 
the hyperploid mitotic cells derived from the 10 µM 
carboplatin treatment, as compared to those generated 
from the higher carboplatin concentrations (20 µM – 40 
µM) (Figure 6G, Supplementary Figure 6B–6D). This 
finding may explain the higher likelihood of successful 
mitotic completion by the hyperploid cells derived from 
the 10 µM carboplatin treatment. Therefore, the capacity 
to produce viable progenies through successful mitoses 
should prompt further consideration of the hyperploid 
pathway as a potential route to continue tumor cell 
survival.
DISCUSSION
We have utilized an in-vitro experimental model 
system, coupled with a robust quantitative image-based 
analysis approach, to systematically study the cellular 
dynamics of tumor cell survivors after platinum treatment. 
This was motivated by observations from patient tumors 
of high grade serous carcinoma after neo-adjuvant 
chemotherapy treatment where a distinct surviving 
subpopulation of large bizarre tumor cells were observed 
in addition to the residual tumor cells retaining the usual 
morphologic features [15–17]. Subpopulation of large 
bizarre tumor cells has been reported in other cancer types 
after radiation or chemotherapy treatment, and may remain 
in the patient for many years. The biological potential and 
clinical implication of these large bizarre cells remain 
unclear.
We showed that platinum treatment induced cell 
cycle arrest at the G2-phase where the bulk tumor cell 
population may undergo DNA damage repair or initiate 
apoptotic death. While these findings were consistent 
with the established literature, we also demonstrated that 
subpopulations of cells exhibited nuclear enlargement as 
a result of exiting the G2-M checkpoint and eventually 
becoming hyperploid. Mechanistically, by assessing 
the strength of the regulator kinase CHK1, it was found 
that the level of phosphorylated CHK1 when normalized 
to the extent of DNA damage might be insufficient to 
maintain G2 arrest at intermediate to late time points. 
This led to aberrant mitotic progression where despite 
the overwhelming number of mitotic catastrophe cell 
deaths, there were occasional mitotic slippage events 
that provided a pathway toward cell survival through a 
subsequent genome polyploidization process.
Interestingly, similar mitotic slippage events have 
been described upon treatment of cells with microtubule-
perturbing drugs [13, 14, 23–26]. These agents appeared 
to produce the initial activation of the spindle assembly 
checkpoint that stalled the progression of mitosis at the 
metaphase-anaphase transition but the durability of this 
blockade was time-limited, eventually giving rise to an 
escape route and leading to a tetraploid G1 state [27]. 
These escaped cells were observed to exhibit large nuclei 
with micronuclei formation and eventually developed 
polyploid genome [14, 28–30]. Indeed, we also observed 
the generation of similar hyperploid cells in the OVCAR3 
in-vitro model after treatment with the microtubule 
polymerization inhibitor nocodazole (Supplementary 
Figure 7A–7H). Although these polyploid tumor cells 
have been shown to bear features of dormancy [14, 22, 
25, 31], we showed by immunofluorescence staining that 
the hyperploid cells from our model system were Ki-67 
positive and remained active in the cell cycle. However, 
this would not necessarily preclude the possibility of 
the hyperploid cells bearing markers of senescence and 
exhibiting certain senescence-like phenotypes, which 
might contribute, through secretory activities, to the 
survival of the bulk population, a possibility that warrants 
future studies. Importantly, additional colony regrowth 
assay demonstrated that while the non-hyperploid 
subpopulation may contribute to the majority of the 
regrowth, there was rare growth by progenies from the 
sorted hyperploid subpopulation. This result suggested 
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Figure 6: Hyperploid tumor cells remained proliferative and retained capacity to generate viable daughter cells. 
Immunofluorescence staining or time-lapse microscopy experiments where adherent OVCAR3 cells maintained within 96-well plates 
were treated with 0 µM to 160 µM carboplatin for 24 hrs on day 0, followed by removal of the drug. Residual cells within the wells were 
then fixed on day 11 for immunofluorescence and Hoechst staining (A–C, F–G), or imaged live by time-lapse microscopy between day 
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that a small subset of the hyperploid cells might retain the 
capacity to repopulate among the regenerating tumor cell 
line. However, there were significant technical limitations 
inherent to the colony regrowth assay which might 
confound the interpretation of these results (i.e. possible 
unique sensitivity of the hyperploid subpopulation toward 
trypsinization, flow sorting process).
To overcome these limitations, we performed live-
cell imaging analysis to follow the fate of the hyperploid 
subpopulation and showed that some of the large mono 
or bi-nucleated tumor cells could undergo successful 
division to generate viable daughter cells. Hence, the 
platinum-induced hyperploid state might not necessarily 
lead to dormancy. Rather, it might serve as an intermediate 
transition point for temporary reprieve of the ongoing 
stresses until cells are poised to revert back to a non-
hyperploid state [32]. Because the capacity to produce 
viable daughter cells was demonstrated for the hyperploid 
cells, we believe the apparent low regrowth potential 
as ascertained from the earlier sorting and regrowth 
experiment does not definitively preclude the possibility 
that the occasional hyperploid cell could contribute to the 
regeneration of the tumor cell line. Future examination, 
utilizing more stringent single-cell tracking technique, 
will be useful to quantify the regrowth potential of the 
hyperploid subpopulation.
The generation of hyperploid cells was also 
observed in the OVCAR3 model after treatment with 
the topoisomerase II inhibitor and DNA intercalator 
doxorubicin, suggesting DNA damage as a common cause 
leading to this hyperploid response (Supplementary Figure 
7I–7L). In addition, the hyperploid response was not 
specific to the OVCAR3 model as it was observed in the 
surviving population across several other ovarian cancer 
cell lines (TOV3133G, PEA1), indicating that this could 
be a generalized cellular response to platinum treatment 
(Supplementary Figure 7M–7O). The features of the 
tumor cell fraction within each cell line that entered this 
hyperploid pathway were not known and might largely be 
stochastic. We propose that a dysfunctional p53 pathway 
might be a contributor to occurrence of this state, as the 
various ovarian cancer cell lines and the SV40 large 
T-antigen transformed lung epithelial cell line (16HBE) that 
exhibited the hyperploid response all shared a commonality 
in p53 alteration as opposed to the non-transformed 
gingival fibroblast cell line (HGF-1) (Supplementary Figure 
7P–7Q). Potentially, baseline perturbations of the G2-M 
cell cycle checkpoint due to p53 pathway alteration could 
lower the threshold governing the entry into the mitotic-
hyperploid pathway after platinum treatment.
In general, the hyperploid pathway was not utilized 
until cell survival fell below 50% (Supplementary Figure 
7O), suggesting that other anti-death processes such as 
anti-apoptotic signaling could be important for maintaining 
survival when the bulk population was treated with 
carboplatin at sub-lethal concentrations. When, however, the 
carboplatin-induced toxicity became overwhelming (i.e. bulk 
population was reduced to 10–20%), there was a substantial 
shift toward the hyperploid response (Supplementary Figure 
7O). We further derived several matched platinum-resistant 
cell lines from the OVCAR3 parent (Supplementary Figure 
7M), and demonstrated substantially lower hyperploid 
response in these daughter cell lines (5–30% for RES1; 
2–10% for RES2) as compared to the parental cell line 
1–2, 4–5, 8–9, 11–12 (D–E). (A) Carboplatin concentration-dependent effect on percentage of non-hyperploid (3N-6N) or hyperploid cells 
with cleaved-PARP positivity on day 11. Cleaved-PARP positivity was defined using mean nuclear intensity and nuclear-to-cytoplasmic 
ratio of the antibody staining to identify cells (~2%) separated from the main viable cluster in the control bulk population. Data points 
were mean percentage of cleaved-PARP positivity +/– standard deviations from 3 independent experiments. Nuclei analyzed ranged from 
20 to about 17000 nuclei per well. *p < 0.05 using two-way ANOVA analysis with Bonferroni’s correction to demonstrate statistically 
significant differences between 0 µM and the indicated carboplatin concentration. (B) Images showing control (top panels) or 16 µM 
carboplatin treated cells (bottom panels) on day 11 with Hoechst staining (left panels) or Ki-67 antibody staining (right panels). Scale bar 
= 20 µm. (C) Carboplatin concentration-dependent effect on nuclear Ki-67 antibody staining positivity for the non-hyperploid (3N-6N) 
or hyperploid subpopulation on day 11. Ki-67 positivity was defined as intensity above background. Data points were mean percentage of 
Ki-67-positivity +/– standard deviations from 3 independent experiments. Nuclei analyzed ranged from 10 to about 15000 nuclei per well. 
(D) Images from time-lapse series taken on day 11 (after prior carboplatin treatment of 10 µM) showing a mono-nucleated large cell (red 
arrowheads) and a bi-nucleated cell (blue arrowheads) going through mitotic slippage while a different bi-nucleated cell (green arrowheads) 
going through successful division. Another large mono-nucleated cell went through catastrophe cell death (orange arrowheads). Scale bar 
= 40 µm. (E) Images from time-lapse series taken on day 11 (after prior carboplatin treatment of 10 µM) showing a bi-nucleated cell going 
through successful tripolar mitosis and generating three daughter cells (green arrowheads). Scale bar = 40 µm. (F) Time and concentration-
dependent effect of carboplatin treatment on percentage of phospho-Histone-H3 positive mitotic nuclei with hyperploid DNA content. 
Nuclei count ranged from 1 to about 15000 nuclei per well. Wells with fewer than five cells or five mitotic nuclei were not included for 
analysis. Data points were mean percentage of mitotic nuclei with hyperploid DNA content +/– standard deviations from 3 independent 
experiments. *p < 0.05 using two-way ANOVA analysis with Bonferroni’s correction to demonstrate statistically significant differences 
for the indicated carboplatin concentration between day 1 and day 11. (G) Concentration-dependent effect of carboplatin treatment on 
percentage of phospho-Histone-H3 positive mitotic nuclei with pH2A.X positivity on day 11. The mitotic nuclei were divided into those 
with non-hyperploid (3N-6N) vs. hyperploid DNA content for this analysis. pH2A.X positivity was defined in the control cells with staining 
intensity higher than the 99.5-percentile level. Nuclei count ranged from 1 to about 15000 nuclei per well. Wells with fewer than five cells 
or five mitotic nuclei were not included for analysis. Data bars were mean percentage of pH2A.X positivity +/– standard deviations from 
3 independent experiments. *p < 0.05 using two-way ANOVA analysis with Bonferroni’s correction to demonstrate statistically significant 
differences for the non-hyperploid (3N-6N)-mitotic nuclei between the two indicated carboplatin concentration.
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Figure 7: Proposed model of the hyperploid pathway as a salvage survival strategy regulated by the G2-M checkpoint. 
Hyperploid pathway as a salvage survival strategy after moderate to high but not extreme concentration of platinum treatment (i.e. 20–100 
uM). After platinum treatment, the activation of the G2-M cell cycle checkpoint led to the initial arrest of tumor cells at the G2-phase for 
DNA damage repair. Under the traditional regeneration pathway, tumor cells that did not perform sufficient DNA damage repair would 
undergo cell death such as by apoptosis or necrosis whereas others that achieved higher level of repair would eventually emerge from the 
G2 arrest and progress through mitosis to produce viable daughter cells. These normal progenies would predominantly contribute to the 
regeneration of the tumor cell line. However, an alternate salvage survival pathway was observed in which some of the initially G2-arrested 
tumor cells with residual DNA damage burden could avoid apoptotic cell death and aberrantly progress through mitosis at an intermediate 
to late time point. The perilous entry into mitosis while carrying residual DNA damage led mostly to mitotic catastrophe cell death. But 
there were occasional tumor cells that managed to exit mitosis via mitotic slippage and thereby avoided mitotic death. Following mitotic 
slippage, subsequent less-defined processes thought to result in the duplication of the genome led these cells to a hyperploid state. Although 
these de novo generated hyperploid tumor cells may continue to persist in this state, some may die while a substantial fraction would 
undergo mitosis. The chance for successful mitotic completion depended critically on the initial platinum treatment concentration and only 
those that were derived from the lowest treatment concentration could produce viable progenies. It remains to be further explored whether 
and how these unique progenies would contribute to the diversity of the regenerating tumor cell line.
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(10–40%), suggesting that a lower extent of hyperploid 
response after platinum treatment might be correlated with 
platinum resistance (Supplementary Figure 7R–7S). The 
lower utilization of the hyperploid pathway could be due 
to strengthening of the G2-M checkpoint by the platinum-
resistant daughter cell lines, perhaps as an adaptation to 
curtail entry into the more perilous hyperploid pathway 
(Supplementary Figure 7T–7V).
We propose an overall model (Figure 7) wherein 
bypassing of apoptosis and entering into a mitotic-
hyperploid pathway after carboplatin treatment might 
represent a salvage survival strategy, a state that 
occurs in the tumor cell population when challenged 
with a moderate to high level (i.e. 20 uM–100 uM) of 
carboplatin. The efficacy of this pathway to produce 
viable progenies was low and highly contingent on 
the initial platinum concentration that generated the 
hyperploid cells. The high attrition rate due to cell death 
throughout the different stages of this pathway would 
largely reduce the initial G2-arrested fraction to the few 
survivors that might emerge after the hyperploid cycle. 
Our study provided evidence that these rare progenies 
might reside within the regenerating tumor cell line. 
Potentially, the coupled process of hyperploidization and 
de-polyploidization might increase the genomic diversity 
of the recovering tumor cell line and contribute to acquired 
platinum resistance. Future studies are warranted to 
define the clinical significance of these hyperploid cells 
by correlating their frequency with clinical outcomes (i.e. 
overall and progression-free survival).
MATERIALS AND METHODS
Cell culture
Cell lines used in this study have been previously 
described: OVCAR3 [19], TOV3133G [33], PEA1 
[34], 16HBE [35], HGF-1 (ATCC CRL-2014) [36]. The 
OVCAR3, TOV3133G and PEA1 ovarian cancer cell 
lines were maintained in RPMI 1640 (Wisent Bioproducts 
350-000-CL) and OSE media (Wisent Bioproducts 316-
030-CL) at a 1:1 ratio and with 6% heat-inactivated fetal 
bovine serum (Invitrogen 12484028) and 1% penicillin-
streptomycin (Gibco 15140122). The 16HBE SV40 
large T antigen transformed lung epithelial cell line 
and the HGF-1 human gingival fibroblast cell line were 
maintained in DMEM (Wisent Bioproducts 319-005-
CL) with 6% FBS and 1% penicillin-streptomycin. Cells 
were plated onto Corning 96-well plates (half area, model 
#3882, VWR #33500-996) for experiments.
In-vitro generation of OVCAR3 carboplatin-
resistant daughter cell lines
The OVCAR3 carboplatin-resistant cell line RES_1 
was generated by treating the parental OVCAR3 cell line 
with 10 µM carboplatin for 24 hours each time, for a total 
of 6 treatments, with approximately one-month interval 
between each treatment. The OVCAR3 carboplatin-
resistant cell line RES_2 was generated by treating the 
parental OVCAR3 cell line with 90 µM carboplatin for 24 
hours, followed by a two month interval, before a second 
treatment with 100 µM carboplatin for 24 hours, and 
followed by a one-month interval before a third treatment 
of 100 µM carboplatin for 24 hours.
Cell viability staining and assessment
Cells were live-stained with 5 µM propidium iodide 
(Sigma Aldrich P4170) and / or 10 µL/mL of CellEvent 
Caspase 3/7 Green indicator (Molecular Probes R37111) 
for 30 min at 37C, for assessment of viability status 
before downstream live imaging or PFA fixation. For 
routine evaluation of cell survival of each well within 
the 96-well plate, cells were processed for PFA fixation 
and downstream permeabilization and Hoechst 33342 
staining (2 uM) for 30 min, followed by PBS washing. 
12 or 15 fields within each well of the 96-well plate 
were imaged by the INCELL 6000 platform, followed by 
automated nuclei detection and mean nuclear fluorescence 
quantification (see below). Single cell level data were 
prepared (see below) and then analyzed within the FlowJo 
program (see below). A minimum threshold level was 
set for the integrated Hoechst nuclear intensity (nuclear 
area x mean Hoechst nuclear fluorescence intensity) to 
help identify nuclei and exclude small / disintegrated 
DNA debris. Then, a threshold level was set for the 
mean nuclear propidium iodide fluorescence intensity, 
above which nuclei were defined as propidium-iodide-
positive and interpreted as non-viable. The propidium-
iodide negative and Hoechst-positive nuclei count was 
taken as the viable cell count within the well. In a typical 
experiment with cytotoxic treatment (i.e. carboplatin), 
three technical replicates (wells) were analyzed for 
each condition and the mean viable cell counts for each 
condition were calculated. The mean viable cell counts for 
a typical time-course experiment (day 1, 4, 7, 11) were 
normalized by the mean viable cell count from the vehicle-
treated wells on day 1, thereby setting cell survival as 1 for 
the control well on day 1.
Pharmacological treatments
Carboplatin (S1532), doxorubicin (S1208), the 
pan-caspase inhibitor Emricasan (S7775), and the CHK1 
kinase inhibitor AZD-7762 (S1532) were obtained from 
Selleckchem. Carboplatin or doxorubicin treatment was 
applied to cells on day 0 for 24 hours and then removed 
on day 1. Where indicated, cells were incubated with 
Emricasan at 2 µM or 5 µM from day 0 or day 1 until 
the end of the experiment. Emricasan was refreshed 
every three to four days with change of media and fresh 
drug incubation. AZD-7762 was added on day 1 after 
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carboplatin was removed, and then maintained throughout 
the rest of the experiment. AZD-7762 was refreshed every 
three to four days with change of media and fresh drug 
incubation. Nocodazole (M1404) was obtained from 
Sigma-Aldrich and applied to cells at 50 nM or 200 nM 
on day 0 continuously for 3 days, followed by fixation and 
downstream processing for staining and analysis.
Time course experiments
Cells were plated onto a set of four 96-well plates 
at 8,000 cells/well three days before carboplatin treatment 
(day -3), and would usually grow to 95–100% confluence 
over the three days. On day 0, carboplatin treatment was 
performed with a concentration scheme of 0 µM, 10 µM, 
20 µM, 40 µM, 80 µM, or 160 µM for 24 hrs. On day 1, 
carboplatin was removed and cells were incubated with 
fresh media. One plate was fixed with PFA 4% for 30 min 
on day 1, 4, 7 or 10–12. The last time point on day 10–
12 would be listed as day 11 throughout the manuscript. 
Media was exchanged every three to four days for the 
remaining plates of the experiment.
Cell line validation
STR-GenePrint analysis of the OVCAR3 parental 
and the matched in-vitro derived resistant daughter cell 
lines (RES_1 and RES_2) were performed by the Sickkids 
Centre for Applied Genomics and Genetic Analysis Facility 
and matched the published profile. The STR Geneprint 
analysis was also performed for the TOV3133G cell line.
Immunofluorescence protocol
Adherent OVCAR3 tumor cells within 96-well 
plates were fixed with 4% paraformaldehyde (Electron 
Microscopy Science 15710) for 30 min and then 
permeabilized with 0.15% Triton X-100 (Sigma-Aldrich 
X100) overnight at 4C. Blocking was performed with 5% 
goat serum (Gibco 16210072) for 1 hour before primary 
antibody incubation overnight at 4C and then incubation 
with fluorescently-conjugated secondary antibody at 
1:2000 for 3–5 hrs. Nuclear staining was performed with 
Hoechst 33342 (Molecular Probes H1399) at 2 µM for 30 
min. At least three to four separate PBS washes were then 
performed before imaging.
Primary antibody incubation buffer (40 µL/well): 
0.015% Triton X-100, 0.1% bovine serum albumin 
(ALB001.250). Secondary antibody incubation buffer (40 
µL/well): 0.1% bovine serum album (ALB001.250).
Primary antibodies
Ki-67 (8D5) (CST9449, mouse, 1:500); Cleaved-
PARP (CST5625, rabbit, 1:350); H2A.X phospho-serine 319 
(clone JBW301) (EMD 05-636, mouse, 1:800); Histone-H3 
phospho-serine 10 (D2C8) (CST3377, rabbit, 1:600); 
CHEK1 phospho-serine 345 (CST2348, rabbit, 1:200).
Secondary antibodies
Goat anti-mouse IgG (H+L) Superclonal 
secondary antibody, Alexa Fluor 488 conjugate 
(Molecular Probes A28175); Goat anti-mouse IgG 
(H+L) F(ab’)2 fragment secondary antibody, Alexa 
Fluor 647 conjugate (CST4410); Goat anti-rabbit IgG 
(H+L) Superclonal secondary antibody, Alexa Fluor 555 
conjugate (Molecular Probes A27039); Goat anti-rabbit 
IgG (H+L) Superclonal secondary antibody, Alexa 
Fluor 647 conjugate (Molecular Probes A27040); Goat 
anti-rabbit IgG (H+L) highly cross-adsorbed secondary 
antibody, Alexa Fluor 488 conjugate (Molecular Probes 
A11034).
Pulse labeling with EdU and Click-iT reaction [37]
Live cells were incubated with 10 µM EdU 
(5-ethynyl-2’-deoxyuridine) (Molecular Probes, C10340) 
for 30 min at 37C to label the S-phase fraction. Cells were 
then fixed with 4% PFA and permeabilized with Triton 
X-100% at 0.15%.
The Click-iT reaction was performed by sequential 
addition of copper sulfate pentahydrate (CuSO4-5H2O) 
[1 mM final] (BioShop CUS803.250), sulfo-cyanine5 
azide [10 µM final] (Lumiprobe B3330) and sodium 
ascorbate [100 mM final] (BioShop ASO704.100) into 
a reservoir of Tris buffer [100 mM pH8.5] (BioShop 
TRS001.5). The sodium ascorbate solution was prepared 
fresh from powder each time. Each component was 
added into the reservoir and mixed well. 40 µL volume 
of the final reaction mixture was then pipetted into each 
well for incubation time of 15 min. Cells were then 
incubated with a PBS wash containing 1.5% BSA for 
15 min.
High-throughput time-lapse imaging of live cells
For preparation of each live-imaging session, 
OVCAR3 cells were plated onto different sections of 
the same 96-well plate on four separate occasions. Cells 
were then allowed to grow to confluence over three days 
before being treated with carboplatin (0 µM to 160 µM) 
at 1, 4, 8, or 11 days before imaging. Each treatment 
condition was technically repeated with four wells within 
the plate. Carboplatin was removed 24 hours after the 
onset of treatment. Immediately prior to imaging, cells 
were first incubated with Hoechst 33342 at 0.8–1 µM for 
30 min at 37C before removal of the Hoechst dye. Then, 
cells were kept in media containing 5 µM propidium 
iodide and 10 µL/mL of the CellEvent caspase 3/7 green 
indicator. Hardware (plate-based) auto-focusing followed 
by imaging was performed every half-hour for a total of 
10 to 24 hours on INCELL Analyzer 6000 (GE Healthcare 
Life Sciences) at 37C and with supply of humidified CO2. 
Images from six to eight random fields per well were 
acquired.
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High-throughput imaging of fixed cells
96-well plates were imaged using the INCELL 
Analyzer 6000 high-content laser scanning confocal 
microscopy system. A set of twelve randomly placed 
fields within each well were imaged, representing up to 
30,000 cells/well. Up to four channels (Hoechst/DAPI, 
FITC, RED, CY5) were acquired for each field. Imaging 
was performed with hardware (plate-based) auto-focusing.
Objective: Nikon 20X (NA = 0.45 Plan Fluor ELWD 
with working distance of 7–8.1 mm; NA = 0.75 Plan 
Apo with working distance of 1 mm); sCMOS Camera 
(2048 x 2048 pixels at 16-bit depth); Excitation with four 
laser lines: 405 nm, 488 nm, 561 mm, 640 nm; Emission 
was captured with polychroic emission filter: 420–490 
nm (Hoechst/DAPI), 505–545 nm (FITC), 569–641 nm 
(RED), 660–753 nm (CY5).
Image processing and analysis
Automated image segmentation was performed 
using a custom image analysis routine for Acapella 2.6 
(PerkinElmer). Image analysis script is available upon 
request. Cell-level data was saved in csv files for each well 
and then converted into FCS format using the freeware 
TextToFCS*. FCS files were imported into FlowJo 
(Flowjo, LLC) cytometry software for analysis.
*http://flowjo.typepad.com/the_daily_dongle/2010/12/
roll-your-own-fcs-files-part-2.html.
For each FCS file, the integrated Hoechst nuclear 
intensity (i.e. Hoechst DNA ploidy histogram) was 
derived by the multiplication of the nuclear area with the 
mean Hoechst nuclear intensity. Gating was applied on 
the integrated Hoechst nuclear intensity to separate the 
subG1 region (debris) from the rest. The propidium iodide 
nuclear intensity was then used to identify propidium-
iodide excluded cells for viability cell count analysis. 
Cell cycle gating was then applied onto the Hoechst DNA 
ploidy histogram, with the position of the G1/(Go), S, 
G2 gates obtained from the EdU horseshoe plots (EdU 
mean nuclear intensity vs. integrated Hoechst nuclear 
intensity). An additional supraG2 gate was applied to the 
right end of the G2 gated region. Numerical data was then 
exported into Prism 7 (GraphPad Software) for plotting 
and statistical analysis.
Time-lapse recording analysis
Mitotic events were visually analyzed and 
categorized as successful division with the generation of 
two or more daughter cells, mitotic catastrophe cell death, 
mitotic slippage, or unclear outcome. All death events 
were calculated as followed: nuclei count (at beginning 
of recording) + # of successful mitoses over the duration 
of recording – nuclei (at end of recording). The rate of 
cell death per hour was the cell death event per hour as a 
percentage of the starting nuclei count. Six to eight imaged 
fields within one representative well were quantified for 
each treatment condition, representing from 0 (i.e. 160 µM 
on day 11–12) to 10000 cells (i.e. control on day 1–2), and 
from 0 (i.e. 160 µM on day 11–12) to 1000 mitotic events 
(i.e. control on day 1–2).
Flow sorting
OVCAR3 cells were either plated within T25 flask 
and treated with vehicle as control, or plated within T125 
flasks and treated with 12.5 µM or 25 µM carboplatin for 
24 hour. Carboplatin was removed on day 1. On day 9 after 
treatment, cells were detached by trypsinization, followed 
by trypsin inactivation with cold PBS supplemented with 
5% FBS, 1% penicillin-streptomycin, 0.1 mM EDTA 
(BioShop EDT001.500). Cells were then spun down and 
incubated on ice in PBS supplemented with 0.5% FBS, 1% 
penicillin-streptomycin, 0.1 mM EDTA, 5 mM HEPES, 1 
µM propidium iodide, and 5 µM Emricasan. Cells were 
then passed through 100 µm nylon mesh cell strainer 
(Falcon 352360). Between 2 to 5 million cells were 
harvested for each experiment, and 1 million cells were 
then pipetted into each polypropylene tube for sorting.
For the sorting experiments with 25 µM carboplatin-
treated cells, three independent experiments involving 
three separate sorting sessions were performed. For the 
sorting experiment with 12.5 µM carboplatin-treated cells, 
two independent experiments were performed. The first 
experiment was performed with a sorting session on day 
9. The second experiment included two different sorting 
sessions on day 8 and day 12 (using additionally prepared 
flasks).
Sorting was performed by dedicated technical 
staffs at the Hospital for Sick Children flow cytometry 
facility. The MoFlo Astrios Sorter (Beckman Coulter 
Life Sciences) was used for cell sorting. Sorting was 
performed by forward scatter (FSC) on a linear scale in 
which FSC distribution ranged from 0 to 256. For the 
control OVCAR3 sample, a FSC gate was placed from 10 
to 64 to define a ‘control – small’ gate for sorting. For the 
OVCAR3 carboplatin treated samples, the same FSC gate 
from 10 to 64 was placed to define a ‘Carboplatin – small’ 
gate while another gate from 150 to 210 was placed to 
define a ‘Carboplatin – large’ gate for sorting. Sorted cells 
were directed by the flow sorter either into each well of a 
96-well plate or into polypropylene tubes.
Serial dilution regrowth assay
Sorted cells were placed into each well of a 96-
well plate at different plating density of 5 cells/well to 
2000–4000 cells/well. Cells were also incubated with 
the pan-caspase inhibitor Emricasan (5 µM) for the 
entire duration of the regrowth assay. Emricasan was 
refreshed every three to four days with change of media 
and fresh drug incubation. The readout of cell growth 
was performed at three weeks after the flow sorting, 
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which corresponded to around day 30 (30 days after the 
initial carboplatin treatment). Cells were incubated with 
propidium iodide before fixation and permeabilization 
for Hoechst staining. The plate was then imaged where 
every well was scanned in its entirety using the INCELL 
Analyzer 6000 platform. The total nuclear count was 
quantified. The pattern of growth was also examined by 
plotting the x and y coordinate of each propidium-iodide 
excluded cell within the well in FlowJo. This enabled 
the identification of growing colonies as well as sparsely 
adherent single cells within the well. The total surface 
area of the well covered by the tumor cell nuclei was also 
quantified and was a good approximation of the extent of 
colony growth.
Pathology review of patient high grade serous 
carcinoma
Patient cases of high grade serous carcinoma from 
the Laboratory Medicine Program at the University Health 
Network (UHN), Toronto were reviewed. Archived H&E 
slides of ten cases of post neo-adjuvant chemotherapy 
treated HGSC and five cases of treatment-naïve HGSC 
were reviewed. Research ethics approval was obtained and 
research conduct guidelines were followed.
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